艾森塔 AZTA

Mr. Lawrence Lin joined Azenta in November 2024 as Executive Vice President and Chief Financial Officer. Mr. Lin is responsible for leading and managing Azenta's global finance functions, including accounting, financial planning and analysis and internal controls. Mr. Lin is also responsible for establishing long-range financial planning and policies while maintaining positive relationships with our shareholders and the financial community. Prior to joining Azenta, Mr. Lin served as Chief Financial Officer of GeoStabilization International LLC, a privately held industrial company specializing in geohazard mitigation, from 2022 to 2024. Before this, from 2021 to 2022, Mr. Lin was Senior Vice President of Finance Operations at PHC Holdings Corporation. Mr. Lin's prior roles include Vice President of Finance for North America (CFO) and Global Functions at LivaNova, a global medtech company, from 2019-2021, and Vice President of Finance Operations at KaVo Kerr, a dental equipment manufacturer previously part of Danaher, from 2016 to 2019. Mr. Lin holds a bachelor's degree in finance from California State University, Fullerton.Mr. Lawrence Lin, the Company's Executive Vice President and Chief Financial Officer, who has also served as the Company's principal accounting officer, will cease to serve as principal accounting officer as of the 31 August 2026 and will continue to serve as Executive Vice President and Chief Financial Officer and as the Company's principal financial officer.

Mr. Ephraim Starr joined Azenta Life Sciences in May 2025 as Senior Vice President, General Counsel & Corporate Secretary, overseeing legal affairs, including governance, securities, litigation, intellectual property, and regulatory matters. He also serves as Secretary to the Corporation and its Board and oversees corporate development. From October 2022 to May 2025, Mr. Starr led the Private Equity Practice at Lean Focus, a consulting firm recognized for cultivating high-performance cultures and driving sustainable growth, and he ran a solo law practice, Ephraim Starr, pllc. From March 2021 to June 2022, he served as General Counsel and Corporate Officer at PHC Holdings, where he supported the company's initial public offering. From 2010 to March 2021, he was the General Counsel of Danaher's Water Platform and served an interim role as Danaher's Chief IP Counsel. Prior to 2010, he held executive legal roles at Lenovo and Honeywell and served as an associate and partner in the litigation and IP departments of Kirkland & Ellis LLP. Mr. Starr holds a J.D. from Duke University School of Law and a B.A. in English and Physics from Amherst College. He is a registered U.S. Patent Attorney and is licensed to practice law in California and Colorado.

Ms. Olga Pirogova joined Azenta in August 2023 as Senior Vice President and Chief Human Resources Officer (CHRO). Ms. Pirogova is responsible for developing and executing Azenta's human resources strategy in support of the overall business plan and strategic direction of the company. Prior to Azenta, from April 2021 to August 2023, Ms. Pirogova served as CHRO at Speedcast, a global satellite communications service provider. Ms. Pirogova spent the previous 12 years with BD (Becton, Dickinson & Company), a leading global medical technology company, where she worked in various Human Resources leadership roles across Latin America, Europe, and the United States. Prior to BD, she worked at British Petroleum and Phillip Morris International, where she held roles in a wide range of HR disciplines. Ms. Pirogova received her master's degree in human development from Ibero-American University in Mexico City and completed her undergraduate degree at Minsk State Linguistic University in Belarus.

Career Highlights: Mr. Casal formerly served as Vice Chair of Audit of KPMG, where he spent over forty years of his career. Having led the Audit function consisting of approximately 9,000 professionals at KPMG, he has proven leadership and management experience, offering unique perspective to the Azenta Board's ongoing efforts to manage talent and human capital. Education: BS, Boston University.

Career Highlights: Since 2000, Ms. Davis has served as Managing Director of AngelHealthcare Investors, a group comprised of Boston-based health and investment leaders. Ms. Davis manages the investment process and the portfolio of early-stage investments including medical devices, life sciences, information technology and professional services. She served on the boards of several portfolio companies and actively contributed to their fundraising, business model, and successful exit. Other Current Public Boards: Psychemedics Corporation. Education: BA, Tufts University; MBA, Harvard University and Executive Master Professional Director Certification, American College of Corporate Directors.

Ms. McLaughlin currently serves as Executive Vice President, CFO and Head of Corporate Strategy at Cabot Corporation (NYSE: CBT), a publicly traded manufacturer of specialty chemicals and performance materials. Ms. McLaughlin joined Cabot in 2002 and has held a variety of roles within the finance organization and Cabot's global businesses, most recently as vice president of business operations for the Reinforcement Materials segment and general manager of the tire business. Prior to joining Cabot, Ms. McLaughlin worked for KPMG, LLP in their audit services division. Education: BS, Boston College and MBA, Boston College.

Dr. Madaus currently serves as a Senior Operating Executive at the Carlyle Group Inc. (NASDAQ: CG), a global investment firm with $382 billion in assets under management. Dr. Madaus has notable experience in strategy, mergers and acquisitions, and commercial transformations, having served as Chairman, President and CEO of Millipore Corporation, where he led their sale to Merck KGaA (FWB:MRK) for $7.2 billion and also led the $4.2 billion leveraged buyout of Ortho Clinical Diagnostics. Dr. Madaus previously served as Chairman and CEO at Other-Clinical Diagnostics and, prior to that, served as President and CEO, N.A. of Roche Diagnostics Corp, a subsidiary of Roche Holdings AG (SWX: ROG). Other Current Public Boards: Repligen Corporation (NASDAQ: RGEN); Quanterix Corporation (NASDAQ: QTRX) and Hologic, Inc. (NASDAQ: HOLX). Former Public Boards: Standard Biotools Inc. (NASDAQ: LAB); Covidien Ltd. (COV) (Acquired by Medtronic plc); Mettler-Toledo International Inc. (NYSE: MTD) and Millipore Corporation (MIL) (Acquired by Merck KGaA). Education: PhD, Veterinary Medicine, Tieraerztliche Hochschule Hannover and DVM, Veterinary Medicine, Ludwig-Maximilians Universitat Munchen. On August 22, 2026, the Board elected Dr. Martin D. Madaus as the Company's Interim President and Chief Executive Officer, effective as of 22nd August 2026.

Dr. Nova has extensive experience in the creation of start-up companies and the commercialization of products with a focus on molecular diagnostics. Dr. Nova spent 15 years as the co-founder, President and CEO of the publicly traded company, Genoptix Medical Laboratories, from inception to its acquisition by Novartis Pharmaceuticals in 2011. She has worked for, managed, raised capital and co-founded a number of early-stage innovative biotechnology companies in San Diego including Nanogen, Inc., Ligand Pharmaceuticals and Hybritech, Inc. Other Current Public Boards: Exagen, Inc. (NASDAQ: XGN). Former Public Boards: Veracyte Inc. (NASDAQ: VCYT) and Arena Pharmaceuticals Inc. (ARNA) (Acquired by Pfizer, Inc.). Education: BS, The University of California, Irvine; PhD, The University of California, Riverside and Postdoctoral Research, New York University Medical Center.

Career Highlights: Mr. Koffey is Founder, Managing Partner and CIO of Politan Capital Management. Prior to founding Politan in 2021, Mr. Koffey was a partner at Senator Investment Group LP from 2019 to 2021, a Portfolio Manager for Strategic Investments at The D.E. Shaw Group from 2017 to 2019 and a Portfolio Manager at Elliott Management Corporation from 2010 to 2017. Other Current Public Boards: Masimo Corporation (NASDAQ: MASI). Education: BA, Yale University; JD, Stanford University and MBA, Stanford University.

Career Highlights: Mr. Cornog is the former head of KKR Capstone, the portfolio operations team of KKR & Co. In addition to leading Capstone, Mr. Cornog chaired KKR's portfolio management committees for the Americas, Europe, Asia, Infrastructure, Impact & Technology Growth and was a member of the Investment & Distribution and Valuation Committees. Other Current Public Boards: Brightview Holdings Inc. (NYSE: BV) and LiveWire (NYSE: LVWR). Education- BA, Stanford University and MBA, Harvard University.

Career Highlights: Mr. Doshi is the CEO of Entrada Therapeutics and a Member of its Board of Directors. He previously served as President and CEO from 2017 to 2023. Mr. Doshi has led critical functions in biotechnology and pharmaceutical companies, including roles focused on business development, corporate strategy, new product planning, commercial planning and finance. Prior to joining Entrada, Mr. Doshi was the Chief Business Officer at Amicus Therapeutics, a global biotechnology company focused on rare diseases. He has also held senior-level positions at a healthcare private equity fund and Catalent. Earlier in his career, Mr. Doshi worked in Merrill Lynch's Investment Banking Group and held several roles at Eli Lilly and Company. Education: BA, Rutgers University and MBA, University of Pennsylvania. Other Current Public Boards: Entrada Therapeutics (NASDAQ: TRDA).

On August 6, 2026, the Board of Directors of Azenta, Inc.appointed Erik J. Bello, as the Company's Vice President, Chief Accounting Officer, effective upon the commencement of his employment with the Company, which is expected to occur on August 31, 2026. Mr. Bello served as Vice President and Corporate Controller of Onto Innovation Inc., a publicly traded semiconductor company, from February 2025 until joining the Company, and as Vice President and Corporate Controller of UniFirst Corporation, a publicly traded provider of workplace uniforms and protective workwear, from October 2020 to February 2025. He previously held senior accounting and financial reporting positions at PAREXEL International Corporation, Mevion Medical Systems, Inc. and Analogic Corporation, and began his career at KPMG LLP. Mr. Bello holds a B.S. in Accounting from the University of Maryland and is a certified public accountant.